Active — Not RecruitingNot Applicable

A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

China153 participantsStarted 2025-01-20

Plain-language summary

The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participant aged 18 years or older * Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and \< 10% * Participant newly initiated deucravacitinib according to the label * Provided written informed consent to participate in the study Exclusion Criteria: * Participating in or planning to participate in an interventional clinical trial * Concomitant use of other systemic treatments for psoriasis at baseline * Prior treatment of deucravacitinib

What they're measuring

Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score

Timeframe: Week 16

Participant psoriasis Body Surface Area (BSA) involvement

Timeframe: Week 16

Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤ 3

Timeframe: Week 16

Trial details

NCT IDNCT06512337

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-03-11

View on ClinicalTrials.gov More Plaque Psoriasis trials